Loading organizations...
Loading organizations...
Based in Pittsburgh, Pennsylvania, D.Sole develops smart foot insoles integrated with a proprietary machine learning platform to provide clinical decision support for the early detection and monitoring of diabetic foot complications. The company's wearable technology fits directly into everyday footwear, allowing healthcare providers, health insurers, and clinical specialists to remotely monitor diabetic patients and proactively manage their preventative treatments. The combined hardware and software system is designed to reduce severe diabetic foot complications by up to 98 percent, which could potentially save health insurers an estimated $8 billion annually. As of January 2025, the health technology startup has raised $125,000 in early-stage venture funding from a syndicate of backers including Rice University and seven other institutional supporters. The medical device company was officially founded in 2022 by biomedical engineer Saisri Akondi and technology lead Jehan Yang.
D.Sole has raised $100K across 1 funding round.
D.Sole has raised $100K in total across 1 funding round.
D.Sole is a health technology company that develops a clinical decision support system using smart foot insoles integrated with machine learning (ML) to enable early detection and monitoring of foot complications in diabetic patients. Their wearable insoles fit into any footwear and provide continuous, remote monitoring, helping reduce diabetic foot complications by up to 98%. This technology serves diabetic patients, clinicians, and insurers by improving patient outcomes, reducing healthcare costs, and enabling proactive care management through data-driven insights and AI-based foot analysis reports[1][2][4].
Founded in 2022 in Pittsburgh, Pennsylvania, D.Sole was co-founded by Saisri Akondi, a biomedical engineer with expertise in medical devices and FDA approvals, and Jehan Yang, who leads the sensor hardware, data collection, and machine learning efforts. The idea emerged from the need to address diabetic peripheral neuropathy, a condition causing loss of foot sensation and leading to severe complications. Early traction came through partnerships with institutions like Rice University, Carnegie Mellon University, and accelerators such as Techstars, which helped refine their business model and technology[2][3].
D.Sole rides the growing trend of wearable health technology and AI-driven clinical decision support systems, addressing a critical need in chronic disease management. The timing is significant due to the increasing prevalence of diabetes (projected to affect 60 million Americans by 2045) and the rising costs associated with diabetic foot complications. Market forces such as value-based care models and the push for remote patient monitoring favor adoption of solutions like D.Sole, which can improve outcomes while lowering costs. Their innovation influences the broader ecosystem by demonstrating how AI and wearables can transform chronic disease management and preventive healthcare[1][4].
D.Sole is poised for growth as it continues to validate its technology through clinical studies and expands partnerships with healthcare providers and insurers. Future trends shaping their journey include increased adoption of AI in healthcare, regulatory support for digital health tools, and growing demand for remote monitoring solutions. As they scale, D.Sole’s influence may extend beyond diabetic foot care to other chronic conditions requiring continuous monitoring, solidifying their role in advancing proactive, data-driven healthcare management[1][2][4].
D.Sole has raised $100K in total across 1 funding round.
D.Sole's investors include Great North Ventures, Innovation Works.
D.Sole has raised $100K across 1 funding round. Most recently, it raised $100K Seed in December 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Dec 1, 2023 | $100K Seed | Great North Ventures, Innovation Works |
